Scientific Information
At present, certain conditions and some patients are considered unsuitable for bone marrow transplantation because of the risk of further complications after a transplant. However, recent findings have shown how these risks can be significantly reduced. AlloStem will use these findings to make bone marrow transplants safer and more effective, enabling more patients to be treated in the future.
Research has shown that after patients have had a transplant an additional infusion of donor blood cells can be targeted to damage harmful cells in the patient's body. AlloStem will develop this method by focusing the donor immune response to specifically target leukaemic cells. The same techniques that are used to eliminate leukaemic cells can also be applied to the more common infectious diseases that afflict patients after a transplant.
By reducing post-transplant illness AlloStem's programme will have a huge social impact, ensuring that a greater number of adults and children will be treated in the future. This will lead to an improvement in healthcare and the development of new pharmaceuticals that will have a dramatic impact on treatment worldwide.
Access to further Scientific Information
If you want to know more about the AlloStem project, please register for access to the Scientific section of this website.
Once you have received your username and password, click here for access.